New name, expanded tools, services and solutions for biotech and biopharma
Halifax, NS – June 5, 2022 – Proteoform Scientific (the Company or Allumiqs), announced today that the Company has a new corporate name, Allumiqs Corporation.
The new name reflects the Company’s evolution, and its goal to deliver an omics platform solution with omics tools, mass spectrometry services and expertise, and data analytics to answer the challenges of biotech customers.
“Allumiqs marks a strategic transformation that moves us beyond proteomics into the growing omics collective and deeper into the omics workflow to elevate the customer experience with mass spec and data analytics,” said Kent MacLean, CEO, Allumiqs. “While the name is a new corporate identity, our founding principles and core values remain unchanged.”
The Company will officially unveil the Allumiqs name this week at the American Society for Mass Spectrometry (ASMS) 70th Conference on Mass Spectrometry and Allied Topics in Minneapolis, MN.
The Company was founded as Proteoform Scientific in 2018 to commercialize a proteomics sample preparation tool created in Dr. Alan Doucette’s laboratory at Dalhousie University. The Company launched the ProTrap XG sample preparation filtration cartridge in 2019 and established a global customer base in academic labs, core facilities, and biotech companies. In 2022, the Company acquired PhenoSwitch Bioscience bioanalytical contract research organization (CRO) to deepen its capabilities in mass spectrometry and data analysis and create a unified multiomics platform solution for sample preparation, mass spectrometry, and data analytics.
About Allumiqs Corporation
Allumiqs Corporation, headquartered in Halifax, Nova Scotia, accelerates the pace of biopharma and biotech discoveries, providing researchers with expertise, tools, and solutions spanning multiomics mass spec workflows from sample prep to data analytics. For more information visit allumiqs.com.